Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/Ib study of DKY709 alone and with PDR001 in advanced solid tumors
jRCT2080224700Phase 1Completed
- Sponsor
- Novartis
- Start
- May 2019
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Phase 1, open-label trial of DKY709 in non-small cell lung cancer (NSCLC), cutaneous melanoma (CM), nasopharyngeal carcinoma (NPC) and 2 more (2 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability of DKY709 alone and in combination with PDR001. Started May 2019; status: completed.
02
Drugs
DKY709
03
Conditions
non-small cell lung cancer (NSCLC)cutaneous melanoma (CM)nasopharyngeal carcinoma (NPC)colorectal cancer (CRC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on jRCT2080224700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224700.